Labels of all extended-release stimulants indicated for ADHD -- including certain formulations of amphetamine and ...

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

The ‘severe, persistent, and disruptive’ shortages often impact patients with ADHD, menopause and diabetes, a new report says ...

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

Medications for attention-deficit/hyperactivity disorder (ADHD) have some side effects that are common, while others are more ...

Kids younger than 6 years on extended-release stimulants for ADHD may experience higher rates of side effects due to higher plasma exposures.

The findings also highlight how shortages severely impact patients with conditions like ADHD, menopause and diabetes.

Instead, participants said, classifying methylphenidate a schedule 6 drug “ negatively impacts on treatment adherence ”. Our medicines regulator, the South African Health Products Regulatory Authority ...

It also highlights the impact that shortages are having on patients with the likes of ADHD (attention deficit hyperactivity ...

The use of stimulant medications to treat ADHD remains stigmatized to some degree. But these medications aren't only effective; they may even promote brain growth.

Stanford University researchers have discovered why some people with attention deficit hyperactivity disorder may do well on their medicine for a while but struggle down the road.

The differing time–action profiles provided by these long-acting MPH formulations may allow clinicians to target specific periods of the day that are particularly relevant for a patient ...